Read by QxMD icon Read

Expert Opinion on Drug Delivery

Siddharth S Kesharwani, Shamandeep Kaur, Hemachand Tummala, Abhay T Sangamwar
A major concern that limits the success of cancer chemotherapy is drug resistance (MDR). The drug resistance mechanisms are either host related, or tumor related. The host tumor interacting factors also contribute to MDR. Multifunctional polymeric micelles offer several advantages in circumventing MDR due to their design, selectivity and stability in cancer microenvironment. Areas covered: The review is broadly divided into two parts the first part covers MDR and its mechanisms. The second part covers multifunctional polymeric micelles in combating MDR through its state-of-the-art design...
October 16, 2018: Expert Opinion on Drug Delivery
Antonella Obinu, Elisabetta Gavini, Giovanna Rassu, Marcello Maestri, Maria Cristina Bonferoni, Paolo Giunchedi
Lymphatic vessels are the preferential route of most solid tumors to spread their metastases in the body. Therefore, the individuation and elimination of cancer cells within the lymphatic system (LS) is an important goal. Nanoparticles (NPs), thanks to their small size, represent suitable carriers for imaging and for chemotherapeutic transport to the LS. An update of different nanoparticle delivery systems developed for detection and treatment of lymphatic metastases has been made, classified from the point of view of the administration routes used...
October 15, 2018: Expert Opinion on Drug Delivery
Basheer Al-Kasmi, Okba Al Rahal, Hind El-Zein, Abdul-Hakim Nattouf
Although many techniques, such as complexation and microencapsulation, are used to mask the unpleasant taste of drugs, the success of all masking processes is evaluated in the same way. To evaluate the success of a masking process, a masked formulation must pass two tests: a structural test and an in vitro in vivo test. Areas covered: This review article highlights structural evaluation and in vitro in vivo evaluation of a taste masking process. The structural evaluation has two criteria: the absence of any chemical interaction between the drug and the masking agent and the molecular distribution of drug in the network of masking agent...
October 12, 2018: Expert Opinion on Drug Delivery
Khalil Abnous, Noor Mohammad Danesh, Mohammad Ramezani, Fahimeh Charbgoo, Amirhossein Bahreyni, Seyed Mohammad Taghdisi
OBJECTIVES: Here, a novel cruciform DNA nanostructure was developed for targeted delivery of doxorubicin (Dox), as an anticancer agent, to lung (A549 cells) and breast (4T1 cells) cancer cells. The cruciform DNA nanostructure consisted of AS1411 aptamer as targeting agent and Forkhead Box Protein M1(FOXM1) aptamer as therapeutic agent. METHODS: MTT assay, fluorescence imaging, flow cytometry analysis, and in vivoantitumor efficacy were performed to evaluate the function of the Dox-DNA nanostructure complex...
September 29, 2018: Expert Opinion on Drug Delivery
Andrew M Bodratti, Paschalis Alexandridis
Nanostructured delivery vehicles can address key challenges facing drug delivery, such as the lipophilic nature of therapeutic compounds and their effective transport through the body. Amphiphilic block copolymers that self-assemble offer advantages compared with homopolymer-, lipid-, and protein-based delivery vehicles. Poly(ethylene oxide)-poly(propylene oxide) amphiphilic block copolymers (Poloxamers) serve well as pharmaceutical excipients because of their highly tunable association properties, low toxicity, and ability to functionalize...
September 27, 2018: Expert Opinion on Drug Delivery
Ikramy A Khalil, Yuma Yamada, Hideyoshi Harashima
The discovery of RNA interference (RNAi) earned the 2006 Nobel Prize in Physiology or Medicine for its biological significance and potential for developing novel therapeutics. The small interfering RNA (siRNA) is the most promising tool for translating RNAi to clinical use. Efforts are ongoing to improve siRNA delivery through developing novel biomaterials and delivery strategies. Given time, it appears that siRNA drugs will eventually become a reality. Areas covered: The currently used approaches for siRNA delivery are discussed with a focus on siRNA therapeutics currently in clinical testing...
September 25, 2018: Expert Opinion on Drug Delivery
Simone Hager, Ernst Wagner
The whole delivery process of nucleic acids is very challenging. Appropriate carrier systems are needed, which show extracellular stability and intracellular disassembly. Viruses have developed various strategies to meet these requirements, as they are optimized by biological evolution to transfer genetic information into host cells. Taking viruses as models, smart synthetic carriers can be designed, mimicking the efficient delivery process of viral infection. These 'synthetic viruses' are pre-programmed and respond to little differences in their microenvironment, caused by either exogenous or endogenous stimuli...
September 24, 2018: Expert Opinion on Drug Delivery
Aoife M Rodgers, Aaron J Courtenay, Ryan F Donnelly
No abstract text is available yet for this article.
September 11, 2018: Expert Opinion on Drug Delivery
Shaheer Maher, Arash Mazinani, Mohammad Reza Barati, Dusan Losic
Therapeutics delivery to bones to treat skeletal diseases or prevent postsurgical infections is challenging due to complex and solid bone structure that limits blood supply and diffusion of therapeutics administered by systemic routes to reach effective concentration. Titanium (Ti) and their alloys are employed as mainstream implant materials in orthopedics and dentistry; having superior mechanical/biocompatibility properties which could provide an alternative solution to address this problem. Areas covered: This review presents an overview of recent development of Ti drug-releasing implants, with emphasis on nanoengineered Titania nanotubes (TNTs) structures, for solving key problems to improve implants osseointegration, overcome inflammation and infection together with providing localized drug delivery (LDD) for bone diseases including cancer...
October 2018: Expert Opinion on Drug Delivery
Mariana Magalhães, Carmen Alvarez-Lorenzo, Angel Concheiro, Ana Figueiras, Ana Cláudia Santos, Francisco Veiga
Despite the current advances in the discovery of the lung cancer biomarkers and, consequently, in the diagnosis, this pathology continues to be the primary cause of cancer-related death worldwide. In most cases, the illness is diagnosed in an advanced stage, which limits the current treatment options available and reduces the survival rate. Therefore, RNAi-based therapy arises as a promising option to treat lung cancer. Areas covered: This review provides an overview on the exploitation of lung cancer biology to develop RNAi-based therapeutics to be applied in the treatment of lung cancer...
October 2018: Expert Opinion on Drug Delivery
Yang Fei Tan, Ying Shi Lee, Li-Fong Seet, Kee Woei Ng, Tina T Wong, Subbu Venkatraman
OBJECTIVES: Clinical translation of siRNA therapeutics has been severely limited due to the lack of stable and sustained siRNA delivery systems. Furthermore, when nanocarrier systems with siRNA are administered systemically to treat diseases, insufficient doses reach the target tissue. Here we report the successful development of a new nanocarrier system for the management of fibrosis. METHODS: The new carrier has a hydroxyapatite core, with alternating layers of siRNA and a cationic peptide...
October 2018: Expert Opinion on Drug Delivery
Wisam Al Bakri, Maureen D Donovan, Maria Cueto, Yunhui Wu, Chinedu Orekie, Zhen Yang
Intranasal (IN) delivery for peptides provides unique advantages compared to other invasive systemic delivery routes. However, there still lacks a clear understanding on how to evaluate the potential of the peptides for nasal delivery and key considerations for the nasal formulation development. Areas covered: A retrospective analysis of intranasally delivered peptides was conducted. The goals of this undertaking were 1) to build a database of the key physicochemical and pharmacokinetic properties of peptides delivered by the nasal route, 2) to evaluate formulation attributes applied to IN peptide delivery systems, and 3) to provide key considerations for IN delivery of peptides...
October 2018: Expert Opinion on Drug Delivery
Forouhe Zahir-Jouzdani, Julian Dominik Wolf, Fatemeh Atyabi, Andreas Bernkop-Schnürch
Mucosal drug delivery is an attractive route of administration, particularly in overcoming deficits of conventional dosage forms including high first-pass metabolism and poor bioavailability. Fast drainage from the target mucosa, however, represents a major limitation as it prevents sufficient drug absorption. In order to address these problems, mucoadhesive in situ gelling drug delivery systems have been investigated as they facilitate easy application in combination with a longer residence time at the administration site resulting in more desirable therapeutic effects...
October 2018: Expert Opinion on Drug Delivery
Marc Brown, Rob Turner, Sean Robert Wevrett
Onychomycosis is the most prevalent nail condition, affecting between 5% and 20% of the population in western countries. Oral therapies are not the treatment of choice due to poor patient compliance, high relapse rates, severe side effects, and contraindication. However, the difficultly in curing the condition using topical delivery is partly due to both the nail structure presenting a complex barrier and the lack of understanding of how best to achieve delivery of drug to the nail bed. Areas covered: Several novel in vitro models incorporating human nails discussed in this article have been developed in recent years that allow for the study of the mechanisms of ungual drug absorption and formulation efficacy to be assessed...
October 2018: Expert Opinion on Drug Delivery
Jiao Wu, Jason Li, Hu Wang, Chang-Bai Liu
Mitochondria are promising targeting organelles for anticancer strategies; however, mitochondria are difficult for antineoplastic drugs to recognize and bind. Mitochondria-penetrating peptides (MPPs) are unique tools to gain access to the cell interior and deliver a bioactive cargo into mitochondria. MPPs have combined or delivered a variety of antitumor cargoes and obviously inhibited the tumor growth in vivo and in vitro. MPPs create new opportunities to develop new treatments for cancer. Areas covered: We review the target sites of mitochondria and the target-penetration mechanism of MPPs, different strategies, and various additional strategies decorated MPPs for tumor cell mitochondria targeting, the decorating mattes including metabolism molecules, RNA, DNA, and protein, which exploited considered as therapeutic combined with MPPs and target in human cancer treatment...
October 2018: Expert Opinion on Drug Delivery
Shymaa Hatem, Maha Nasr, Noha H Moftah, Maha H Ragai, Ahmed S Geneidi, Seham A Elkheshen
BACKGROUND: The present work aims to formulate nanostructured lipid carriers (NLCs) exhibiting high skin deposition and high inherent antioxidant potential to repurpose the use of melatonin hormone and some antioxidant oils in the treatment of androgenic alopecia (AGA). RESEARCH DESIGN AND METHODS: NLCs were characterized for their size, charge, drug entrapment, anti-oxidant potential, physical stability, in vitro release, surface morphology, and ex-vivo skin deposition...
October 2018: Expert Opinion on Drug Delivery
Vu Thanh Cong, Katharina Gaus, Richard D Tilley, J Justin Gooding
Interest in mesoporous silica nanoparticles for drug delivery has resulted in a good understanding of the impact of size and surface chemistry of these nanoparticles on their performance as drug carriers. Shape has emerged as an additional factor that can have a significant effect on delivery efficacy. Rod-shaped mesoporous silica nanoparticles show improvements in drug delivery relative to spherical mesoporous silica nanoparticles. Areas covered: This review summarises the synthesis methods for producing rod-shaped mesoporous silica nanoparticles for use in nanomedicine...
September 2018: Expert Opinion on Drug Delivery
Gilles Sebastiaan van Tienderen, Marius Berthel, Zhilian Yue, Mark Cook, Xiao Liu, Stephen Beirne, Gordon G Wallace
INTRODUCTION: Epilepsy is a chronic brain disease characterized by unprovoked seizures, which can have severe consequences including loss of awareness and death. Currently, 30% of epileptic patients do not receive adequate seizure alleviation from oral routes of medication. Over the last decade, local drug delivery to the focal area of the brain where the seizure originates has emerged as a potential alternative and may be achieved through the fabrication of drug-loaded polymeric implants for controlled on-site delivery...
September 2018: Expert Opinion on Drug Delivery
Di Wang, Yating Sun, Yange Liu, Fanchao Meng, Robert J Lee
INTRODUCTION: Liposomes have been extensively investigated as drug delivery vehicles. Immunoliposomes (ILs) are antibody-conjugated liposomes designed to selectively target antigen-expressing cells. ILs can be used to deliver drugs to tumor cells for improving efficacy and reducing toxicity. In addition, ILs can be used in immunoassays, immunotherapy, and imaging. Although there has been extensive coverage on ILs in the literature, only a limited number of clinical trials have been reported and no IL drug has been approved by the FDA...
September 2018: Expert Opinion on Drug Delivery
D C Luther, Y W Lee, H Nagaraj, F Scaletti, V M Rotello
Therapeutic gene editing is becoming a viable biomedical tool with the emergence of the CRISPR/Cas9 system. CRISPR-based technologies have promise as a therapeutic platform for many human genetic diseases previously considered untreatable, providing a flexible approach to high-fidelity gene editing. For many diseases, such as sickle-cell disease and beta thalassemia, curative therapy may already be on the horizon, with CRISPR-based clinical trials slated for the next few years. Translation of CRISPR-based therapy to in vivo application however, is no small feat, and major hurdles remain for efficacious use of the CRISPR/Cas9 system in clinical contexts...
September 2018: Expert Opinion on Drug Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"